Compare FISI & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FISI | AURA |
|---|---|---|
| Founded | 1817 | 2007 |
| Country | United States | United States |
| Employees | 631 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 713.0M | 713.4M |
| IPO Year | N/A | 2021 |
| Metric | FISI | AURA |
|---|---|---|
| Price | $38.04 | $6.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $37.00 | $20.00 |
| AVG Volume (30 Days) | 157.1K | ★ 517.1K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.76% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.22 | N/A |
| P/E Ratio | $9.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.62 | $4.73 |
| 52 Week High | $39.19 | $9.54 |
| Indicator | FISI | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 61.49 | 50.16 |
| Support Level | $36.43 | $5.86 |
| Resistance Level | N/A | $7.81 |
| Average True Range (ATR) | 0.82 | 0.41 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 60.12 | 64.89 |
Financial Institutions Inc operates through its subsidiaries, providing full range of banking services to consumer, commercial and municipal customers in Western and Central New York, and commercial loans in the Mid-Atlantic region, through a loan production office in Ellicott City, Maryland. It offers a broad range of loans including commercial business and revolving lines of credit, commercial mortgages, equipment loans, residential mortgage loans and home equity loans and lines of credit, automobile loans and personal loans. It operates in single segment of Banking.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.